Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Phase 4
125
about 4.7 years
18–89
4 sites in NY
What this study is about
Researchers are testing whether lowering cholesterol can improve platelet function, white blood cell gene expression, and vascular function in people with type 1 diabetes. The trial will follow participants for about two years to observe these effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 18F-FDG
- 2.Take Atorvastatin Calcium Tablets
- 3.Take Evolocumab Cartridge
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fludeoxyglucose (18F), atorvastatin (Statin; inhibits HMG-CoA reductase to lower cholesterol), CARDIOVASCULAR SYSTEM, ezetimibe (Cholesterol absorption inhibitor; reduces intestinal cholesterol uptake)
oral, subcutaneous
Endocrinology